{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:00:45Z","timestamp":1790910045455,"version":"4.1.0"},"reference-count":111,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for severe aplastic anemia (SAA). In China, the number of SAA patients undergoing allo-HSCT has risen considerably. However, owing to variations in clinical practices between China and other countries, certain aspects of transplantation demonstrate unique and distinct characteristics. To address these unique challenges and standardize clinical practice, we developed evidence-based guidelines tailored to the management of Chinese SAA patients undergoing allo-HSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This clinical practice guideline was developed using the Evidence to Decision framework and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to formulate evidence-based recommendations. In instances where high-quality evidence was lacking, the Delphi method was used to integrate expert opinions. The guidelines adhere to the Appraisal of Guidelines for Research and Evaluation II (AGREE II) framework and the Reporting Items for Practice Guidelines in Health Care (RIGHT) statement to ensure methodological rigor and transparency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The guidelines present 32 recommendations encompassing key aspects of allo-HSCT for SAA, including patient eligibility criteria, donor and graft selection, pretransplant assessment, conditioning strategies, graft-versus-host disease prophylaxis, early management of posttransplant complications, and long-term follow-up. These recommendations are based on the latest clinical evidence and expert consensus, offering a structured approach to optimize transplantation outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These guidelines establish standardized protocols to enhance allo-HSCT management for SAA in China by integrating current evidence and expert consensus. Its widespread adoption is expected to improve donor selection strategies, conditioning regimen applications, posttransplant care, and long-term patient outcomes. Ultimately, these recommendations aim to increase the quality of patient care, improve survival rates, and contribute to the advancement of national health care standards.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003917","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:00:09Z","timestamp":1767178809000},"page":"322-340","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Chinese Society of Hematology clinical practice guidelines for the comprehensive management of allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia"],"prefix":"10.1097","volume":"139","author":[{"given":"Lanping","family":"Xu","sequence":"first","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Xinqiao Hospital of Army Medical University (Third Military Medical University), Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"R1-20260205","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.19236","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia: A british society for haematology guideline","volume":"204","author":"Kulasekararaj","year":"2024","journal-title":"Br J Haematol"},{"key":"R2-20260205","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood-2005-01-0161","article-title":"The epidemiology of aplastic anemia in Thailand","volume":"107","author":"Issaragrisil","year":"2006","journal-title":"Blood"},{"key":"R3-20260205","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1096-8652(199907)61:3<164::AID-AJH2>3.0.CO;2-R","article-title":"Regional patterns in the incidence of aplastic anemia in Thailand. The aplastic anemia study group","volume":"61","author":"Issaragrisil","year":"1999","journal-title":"Am J Hematol"},{"key":"R4-20260205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF03165112","article-title":"Aplastic anemia in the Orient","volume":"76","author":"Kojima","year":"2002","journal-title":"Int J Hematol"},{"key":"R5-20260205","first-page":"284","article-title":"Incidence of adult aplastic anemia in Shanghai, China","volume":"50","author":"Wang","year":"2011","journal-title":"Chin J Intern Med"},{"key":"R6-20260205","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000499065","article-title":"Current treatment patterns of aplastic anemia in China: A prospective cohort registry study","volume":"142","author":"Zhu","year":"2019","journal-title":"Acta Haematol"},{"key":"R7-20260205","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.4103\/0366-6999.240810","article-title":"Relationship of cell compositions in allografts with outcomes after haploidentical transplantation for acquired severe aplastic anemia: effects of CD34+ and CD14+ cell doses","volume":"131","author":"Cao","year":"2018","journal-title":"Chin Med J"},{"key":"R8-20260205","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3324\/haematol.2022.280758","article-title":"Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: A national registry-based study","volume":"107","author":"Xu","year":"2022","journal-title":"Haematologica"},{"key":"R9-20260205","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.scib.2022.01.024","article-title":"Long-term follow-up of haploidentical transplantation in relapsed\/refractory severe aplastic anemia: A multicenter prospective study","volume":"67","author":"Xu","year":"2022","journal-title":"Sci Bull (Beijing)"},{"key":"R10-20260205","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13810","article-title":"Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: A retrospective multicenter cohort study","volume":"34","author":"Zhang","year":"2020","journal-title":"Clin Transplant"},{"key":"R11-20260205","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41409-024-02419-8","article-title":"Hematopoietic stem cell transplantation activity in china 2022- 2023. The proportions of peripheral blood for stem cell source continue to grow: A report from the Chinese blood and mar\u00adrow transplantation registry group","volume":"59","author":"Xu","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"R12-20260205","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"R13-20260205","article-title":"Treatment of relapsed\/refractory severe aplastic anemia in children: Evidence-based recommendations","volume":"71","author":"Shimano","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20260205","article-title":"Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations","volume":"71","author":"Shimano","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"R15-20260205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2024.102860","article-title":"Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the marrow failure study group of the pediatric haemato-oncology Italian association (AIEOP)","volume":"108","author":"Guarina","year":"2024","journal-title":"Blood Cells Mol Dis"},{"key":"R16-20260205","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jtct.2024.09.017","article-title":"Allogeneic hematopoietic cell transplanta\u00adtion for the treatment of severe aplastic anemia: Evidence-based guidelines from the American society for transplantation and cellular therapy","volume":"30","author":"Iftikhar","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R17-20260205","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1182\/bloodadvances.2023011642","article-title":"Modified Delphi panel consensus recommendations for management of severe aplastic anemia","volume":"8","author":"Babushok","year":"2024","journal-title":"Blood Adv"},{"key":"R19-20260205","first-page":"253","article-title":"Recommendations for the management of acute immune thrombocytopenia in children. A Consensus Conference from the Italian Association of Pediatric Hematology and Oncology","volume":"22","author":"Russo","year":"2024","journal-title":"Blood Transfus"},{"key":"R20-20260205","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a744","article-title":"Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive","volume":"337","author":"Jaeschke","year":"2008","journal-title":"BMJ"},{"key":"R21-20260205","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: Advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"key":"R22-20260205","doi-asserted-by":"crossref","first-page":"128","DOI":"10.7326\/M16-1565","article-title":"A reporting tool for practice guidelines in health care: The RIGHT statement","volume":"166","author":"Chen","year":"2017","journal-title":"Annals of internal medicine"},{"key":"R23-20260205","first-page":"881","article-title":"Guidelines for the diagnosis and management of aplastic anemia in China (2022)","volume":"43","year":"2022","journal-title":"Chin J Hematol"},{"key":"R24-20260205","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41409-024-02377-1","article-title":"First-line treatment of severe aplastic anemia: Immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study","volume":"59","author":"Liu","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"R25-20260205","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-023-05256-9","article-title":"Comparison of haploidentical-allogeneic hematopoietic stem cell transplantation and intensive immunosuppressive therapy for patients with severe aplastic anemia with an absolute neutrophil count of zero: A retrospective study","volume":"102","author":"Wu","year":"2023","journal-title":"Ann Hematol"},{"key":"R26-20260205","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/ejh.13057","article-title":"Low response rate to ATG-based immunosuppressive therapy in very severe aplastic anaemia - A Swedish nationwide cohort study","volume":"100","author":"Vaht","year":"2018","journal-title":"Eur J Haematol"},{"key":"R27-20260205","article-title":"Development and validation of early death risk score model for emergency status prediction in very severe aplastic anemia","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"R28-20260205","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41375-022-01636-8","article-title":"Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia","volume":"36","author":"Groarke","year":"2022","journal-title":"Leukemia"},{"key":"R29-20260205","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.scib.2022.01.024","article-title":"Long-term follow-up of haploidentical transplantation in relapsed\/refractory severe aplastic anemia: A multicenter prospective study","volume":"67","author":"Xu","year":"2022","journal-title":"Science Bull (Beijing)"},{"key":"R30-20260205","first-page":"726","article-title":"The role of mesenchymal stem cells in allogeneic hematopoietic stem cell transplantation for patients with refractory severe aplastic nemia","volume":"40","author":"Zhao","year":"2019","journal-title":"Chin J Hematol"},{"key":"R31-20260205","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.7150\/ijms.94012","article-title":"Haploidentical hematopoietic stem cell transplantation as a first-line treatment for paediatric severe aplastic anemia: a single-center research","volume":"21","author":"Yuan","year":"2024","journal-title":"Int J Med Sci"},{"key":"R32-20260205","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41409-025-02617-y","article-title":"Clinical outcomes of offspring and matched unrelated donor transplant in relapsed or refractory severe aplastic anemia patients aged 40-50: A retrospective analysis from the CBMTR over the past decade","volume":"60","author":"Zhao","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"R33-20260205","first-page":"2000","article-title":"The outcome of allogeneic hematopoietic stem cell transplantation among elderly patients with severe aplastic anemia and a predictive model from the Chinese blood and marrow transplant registry group","volume":"109","author":"Xu","year":"2024","journal-title":"Haematologica"},{"key":"R34-20260205","article-title":"Inefficacy of immunosuppressive therapy for severe aplastic anemia progressing from non-SAA: Improved outcome after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"R35-20260205","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/bjh.18779","article-title":"Haemato\u00adpoietic stem cell transplantation for hepatitis-associated aplastic anaemia and non-hepatitis-associated aplastic anaemia: A propen\u00adsity score-matched analysis","volume":"201","author":"Li","year":"2023","journal-title":"Br J Haematol"},{"key":"R36-20260205","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s00277-022-04885-w","article-title":"Comparable clinical outcomes of haploidentical hematopoietic stem cell transplantation in patients with hepatitis-associated aplastic anemia and non-hepatitis-associated aplastic anemia","volume":"101","author":"Ma","year":"2022","journal-title":"Ann Hematol"},{"key":"R37-20260205","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.bbmt.2020.05.024","article-title":"Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: Multicenter analysis by the Polish adult leukemia group","volume":"26","author":"Markiewicz","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R38-20260205","first-page":"472","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria compared to paroxysmal nocturnal hemoglobinuria-aplastic anemia syndrome","volume":"40","author":"Liu","year":"2019","journal-title":"Chin J Hematol"},{"key":"R39-20260205","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/s41409-020-0820-x","article-title":"Comparison of HLA-matched sibling and unrelated donor transplantation in adult patients with acquired severe aplastic anemia","volume":"55","author":"Shin","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R40-20260205","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bjh.13614","article-title":"Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK paediatric BMT working party, paediatric diseases working party and severe aplastic anaemia working party of EBMT","volume":"171","author":"Dufour","year":"2015","journal-title":"Br J Haematol"},{"key":"R41-20260205","first-page":"781","article-title":"Similar outcomes between HLA-haploid and matched sibling donor hematopoietic stem cell transplantation: A multicenter, retrospective study and severe aplastic anemia transplant-specific prognostic scoring system","volume":"104","author":"Gao","year":"2025","journal-title":"Ann Hematol"},{"key":"R42-20260205","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41409-018-0410-3","article-title":"Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia","volume":"54","author":"Xu","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R43-20260205","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-017-0398-y","article-title":"Upfront haploidentical transplant for acquired severe aplastic anemia: Registry-based comparison with matched related transplant","volume":"10","author":"Xu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R44-20260205","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217594","article-title":"Comparable survival outcomes in HLA-matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40-50: A CBMTR registry-based propensity score matching analysis over the last decade","volume":"621","author":"Xu","year":"2025","journal-title":"Cancer Lett"},{"key":"R45-20260205","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jtct.2024.09.005","article-title":"ASTCT consensus recommendations on testing and treatment of patients with donor-specific anti-HLA antibodies","volume":"30","author":"Kongtim","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R46-20260205","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/bmt.2011.131","article-title":"Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT","volume":"47","author":"Yoshihara","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R47-20260205","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-015-0182-9","article-title":"Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: A prospective study with randomly assigned training and validation sets","volume":"8","author":"Chang","year":"2015","journal-title":"J Hematol Oncol"},{"key":"R48-20260205","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from the Chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R49-20260205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-019-0775-9","article-title":"Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study","volume":"12","author":"Xu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R50-20260205","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R51-20260205","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41409-020-0779-7","article-title":"Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia","volume":"55","author":"Ma","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R52-20260205","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/j.bbmt.2018.07.018","article-title":"Allogeneic hematopoietic stem cell transplantation for the treatment o f severe aplastic anemia patients with infection: A single-center retrospective study","volume":"24","author":"Xu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R53-20260205","article-title":"Severe aplastic anemia patients with infection who received an allogeneic hematopoietic stem cell transplantation had a better chance: Long-term outcomes of a multicenter study","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"R54-20260205","article-title":"The prognostic impact of previously infectious complications on allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia: A single-center, retrospective study","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"R55-20260205","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1080\/10428194.2022.2118527","article-title":"Comparisons of unmanipulated haploidentical donor, unrelated cord blood donor and matched unrelated donor hematopoietic stem cell transplantation in pediatric acquired severe aplastic anemia: A single center study","volume":"63","author":"Lu","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"R56-20260205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-024-01021-x","article-title":"Unrelated donor hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for adults with severe aplastic anemia","volume":"14","author":"Wu","year":"2024","journal-title":"Blood Cancer J"},{"key":"R57-20260205","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.17916","article-title":"Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation","volume":"196","author":"Xu","year":"2022","journal-title":"Br J Haematol"},{"key":"R58-20260205","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/10245332.2017.1390929","article-title":"Serum ferritin is a different predictor from transfusion history for allogeneic transplantation outcome in patients with severe aplastic anemia","volume":"23","author":"Zhang","year":"2018","journal-title":"Hematology"},{"key":"R59-20260205","doi-asserted-by":"crossref","first-page":"507.e1","DOI":"10.1016\/j.jtct.2023.04.016","article-title":"Impact of iron overload and iron chelation with deferasirox on outcomes of patients with severe aplastic anemia after allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Pan","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R60-20260205","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/bmt.2017.147","article-title":"Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the consensus of the pediatric diseases working party of the EBMT and the international BFM study group","volume":"52","author":"Balduzzi","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"R61-20260205","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.3390\/jcm12175449","article-title":"Comparison of different rabbit anti-thymocyte globulin formulations in the prophylaxis of graft-versus-host disease: A systematic review","volume":"12","author":"Dybko","year":"2023","journal-title":"J Clin Med"},{"key":"R62-20260205","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41409-018-0393-0","article-title":"Antithymocyte globulin for graft-versus-host disease prophylaxis: An updated systematic review and meta-analysis","volume":"54","author":"Kumar","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R63-20260205","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dul\u00e9ry","year":"2021","journal-title":"JACC CardioOncol"},{"key":"R64-20260205","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00277-016-2654-6","article-title":"The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT)","volume":"95","author":"Ishida","year":"2016","journal-title":"Ann Hematol"},{"key":"R65-20260205","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41409-019-0509-1","article-title":"Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantation","volume":"54","author":"Xu","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R66-20260205","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.bbmt.2010.05.010","article-title":"Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study","volume":"16","author":"Kang","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R67-20260205","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.bbmt.2016.04.003","article-title":"Improved outcome of a reduced toxicity-fludarabine, cyclophosphamide, plus antithymocyte globulin conditioning regimen for unrelated donor transplantation in severe aplastic anemia: Comparison of 2 multicenter prospective studies","volume":"22","author":"Kang","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R68-20260205","doi-asserted-by":"crossref","first-page":"808.e1","DOI":"10.1016\/j.jtct.2025.06.014","article-title":"Comparative study of Bu\/Cy\/ATG and Flu\/Cy\/ATG conditioning regimens for unrelated donor hematopoietic stem cell transplantation in severe aplastic anemia","volume":"31","author":"Wu","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"R69-20260205","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14160","article-title":"The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia","volume":"35","author":"Xu","year":"2021","journal-title":"Clin Transplant"},{"key":"R70-20260205","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.956867","article-title":"Gynecological complications in long-term survivors after allogeneic hematopoietic cell transplantation-a single-center real-life cross-sectional study","volume":"9","author":"Su","year":"2022","journal-title":"Front Med"},{"key":"R71-20260205","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/bmt.2011.78","article-title":"Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence","volume":"47","author":"Borgmann-Staudt","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R72-20260205","doi-asserted-by":"crossref","first-page":"1099.e1","DOI":"10.1016\/j.jtct.2024.08.016","article-title":"Efficacy of a modified post-transplant cyclophosphamide regimen for unrelated donor hematopoietic stem cell transplantation in patients with severe aplastic anemia: A prospective study","volume":"30","author":"Chen","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R73-20260205","doi-asserted-by":"crossref","first-page":"463.e1","DOI":"10.1016\/j.jtct.2023.04.015","article-title":"Prospective study of a modified post-transplantation cyclophosphamide regimen for severe aplastic anemia patients with HLA-haploidentical transplantation","volume":"29","author":"Wu","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R74-20260205","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3324\/haematol.2009.018267","article-title":"Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: A retrospective study from the EBMT-SAA working party","volume":"95","author":"Bacigalupo","year":"2010","journal-title":"Haematologica"},{"key":"R75-20260205","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1159\/000531687","article-title":"Busulfan for allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia: A retrospective study","volume":"146","author":"Si","year":"2023","journal-title":"Acta Haematol"},{"key":"R76-20260205","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/bmt.2017.237","article-title":"Unmanipulated haploidentical transplantation conditioning with busulfan, cyclophosphamide and anti-thymoglobulin for adult severe aplastic anaemia","volume":"53","author":"Xu","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"R77-20260205","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00277-012-1462-x","article-title":"A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome","volume":"91","author":"Kim","year":"2012","journal-title":"Ann Hematol"},{"key":"R79-20260205","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1182\/blood-2024-208246","article-title":"Comparison of two conditioning regimens for haploidentical stem cell transplantation in patients with severe aplastic anemia","volume":"144","author":"Lin","year":"2024","journal-title":"Blood"},{"key":"R80-20260205","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1016\/j.transproceed.2021.07.004","article-title":"First-line unrelated double-unit umbilical cord blood transplantation for acquired severe aplastic anemia","volume":"53","author":"Liu","year":"2021","journal-title":"Transplant Proc"},{"key":"R81-20260205","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00277-024-05756-2","article-title":"Unrelated umbilical cord blood transplantation with low-dose anti-thymocyte globulin for children with severe aplastic anemia: A case series","volume":"103","author":"Hu","year":"2024","journal-title":"Ann Hematol"},{"key":"R82-20260205","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1038\/s41409-021-01431-6","article-title":"Hematopoietic stem cell transplantation activity in China 2019: A report from the Chinese blood and marrow transplantation registry group","volume":"56","author":"Xu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R83-20260205","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1289180","article-title":"Peripheral blood stem cell transplantation vs. bone marrow transplantation for aplastic anemia: A systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Med"},{"key":"R85-20260205","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1016\/j.transproceed.2019.07.029","article-title":"Combination of HLA-matched sibling allogeneic hematopoietic stem cell transplantation with unrelated cord blood unit in patients aged 35 to 50 years with severe aplastic anemia: Preliminary summary of a single-arm trial","volume":"51","author":"Yang","year":"2019","journal-title":"Transplant Proc"},{"key":"R86-20260205","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.12405","article-title":"Allogeneic stem cell transplantation for children with acquired severe aplastic anaemia: A retrospective study by the Viva-Asia blood and marrow transplantation group","volume":"162","author":"Chen","year":"2013","journal-title":"Br J Haematol"},{"key":"R87-20260205","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41409-024-02419-8","article-title":"Hematopoietic stem cell transplantation activity in China 2022\u20132023. The proportions of peripheral blood for stem cell source continue to grow: A report from the Chinese blood and marrow transplantation registry group","volume":"59","author":"Xu","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"R88-20260205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1384640","article-title":"Comparison of upfront haploidentical hematopoietic stem cell transplantation and salvage haploidentical hematopoietic stem cell transplantation after immunosuppressive therapy in children with acquired severe aplastic anemia-A multicenter study","volume":"15","author":"Luo","year":"2024","journal-title":"Front Immunol"},{"key":"R89-20260205","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(22)00206-X","article-title":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): A multicentre, single-arm, phase 2 trial","volume":"9","author":"DeZern","year":"2022","journal-title":"Lancet Haematol"},{"key":"R90-20260205","first-page":"65","article-title":"The \u201cBeijing protocol\u201d for haploidentical hematopoietic stem cell transplantation","volume":"38","author":"Huang","year":"2017","journal-title":"Chin J Organ Transplant"},{"key":"R91-20260205","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/bmt.2012.79","article-title":"A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia","volume":"47","author":"Xu","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R92-20260205","doi-asserted-by":"crossref","first-page":"331.e1","DOI":"10.1016\/j.jtct.2021.01.018","article-title":"Haploidentical transplantation with modified post-transplantation cyclophosphamide for patients with primary aplastic anemia: A multicenter experience","volume":"27","author":"Li","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R93-20260205","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fimmu.2016.00507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol"},{"key":"R94-20260205","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/17843286.2020.1754635","article-title":"Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature","volume":"76","author":"Delie","year":"2021","journal-title":"Acta Clin Belg"},{"key":"R95-20260205","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/16078454.2021.1938422","article-title":"Mixed chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia","volume":"26","author":"Zhang","year":"2021","journal-title":"Hematology"},{"key":"R96-20260205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154737","article-title":"Long-Term stable mixed chimerism after hematopoietic stem cell transplantation in patients with non-malignant disease, shall we be tolerant?","volume":"11","author":"Stikvoort","year":"2016","journal-title":"PloS one"},{"key":"R97-20260205","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70059","article-title":"Definitions matter: Multicenter investigation of incidence and outcome of poor graft function after hematopoietic cell transplantation","volume":"8","author":"M\u00fcskens","year":"2024","journal-title":"Hemasphere"},{"key":"R98-20260205","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/s41375-021-01294-2","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis: Proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT chronic malignancies working party","volume":"35","author":"McLornan","year":"2021","journal-title":"Leukemia"},{"key":"R99-20260205","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.transci.2018.04.014","article-title":"Graft failure after allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Ozdemir","year":"2018","journal-title":"Transfus Apher Sci"},{"issue":"Suppl 1","key":"R100-20260205","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2298\/MPNS22S1045T","article-title":"Poor graft function- Causes and potential solutions","volume":"75","author":"Todorovi\u0107-Balint","year":"2022","journal-title":"Med Pregl"},{"key":"R101-20260205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1106464","article-title":"Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis","volume":"14","author":"Servais","year":"2023","journal-title":"Front Immunol"},{"key":"R102-20260205","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1182\/bloodadvances.2023012418","article-title":"Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival","volume":"8","author":"Shapiro","journal-title":"Blood Adv"},{"key":"R103-20260205","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/bloodadvances.2024013581","article-title":"A boost for poor graft function","volume":"8","author":"Mohty","year":"2024","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"R105-20260205","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1182\/blood-2024-205561","article-title":"Changing donor was critical for the successful salvage second transpla ntation for graft failure after the first allogeneic stem cell transpl antation: A Chinese multicenter retrospective study","volume":"144","author":"Ma","year":"2024","journal-title":"Blood"},{"key":"R106-20260205","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood-2009-06-229369","article-title":"Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: A report from the bone marrow transplant survivor study","volume":"116","author":"Sun","year":"2010","journal-title":"Blood"},{"key":"R107-20260205","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/cncr.34575","article-title":"Severe, life-threatening, and fatal chronic health conditions after allogeneic blood or marrow transplantation in childhood","volume":"129","author":"Holmqvist","year":"2023","journal-title":"Cancer"},{"key":"R108-20260205","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2024024173","article-title":"Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT","volume":"144","author":"Montoro","year":"2024","journal-title":"Blood"},{"key":"R109-20260205","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.4103\/0366-6999.240810","article-title":"Relationship of cell compositions in allografts with outcomes after haploidentical transplantation for acquired severe aplastic anemia: Effects of CD34+ and CD14+ cell doses","volume":"131","author":"Cao","year":"2018","journal-title":"Chin Med J"},{"key":"R110-20260205","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"key":"R111-20260205","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41409-023-02117-x","article-title":"Peripheral blood stem cell transplantation from haploidentical related donor could achieve satisfactory clinical outcomes for intermediate or high-risk adult acute myeloid leukemia patients","volume":"59","author":"Cao","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"R112-20260205","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jare.2014.11.001","article-title":"Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders","volume":"6","author":"Mahmoud","year":"2015","journal-title":"J Adv Res"},{"key":"R113-20260205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.912917","article-title":"Comparison of haploidentical hematopoietic stem cell transplant with or without unrelated cord blood infusion in severe aplastic anemia: Outcomes of a multicenter study","volume":"13","author":"Lei","year":"2022","journal-title":"Front Immunol"},{"key":"R114-20260205","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s13312-022-2538-x","article-title":"Diagnosis and management of acquired aplastic anemia: consensus statement of Indian academy of pediatrics","volume":"59","author":"Danewa","year":"2022","journal-title":"Indian Pediatri"},{"key":"R115-20260205","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.35365","article-title":"Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European society for blood and marrow transplantation acute leukemia working party","volume":"130","author":"Bazarbachi","year":"2024","journal-title":"Cancer"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:50:27Z","timestamp":1786035027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":111,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003917","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"2025-05-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}